Your session is about to expire
← Back to Search
Combination of Mirvetuximab + SL-172154 and Combination of Pegylated Liposomal Doxorubicin + SL-172154 for Ovarian Cancer
This trial is testing a new drug, SL-172154, to see if it is safe and effective when used with other drugs to treat ovarian cancer.
- Fallopian Tube Carcinoma
- Peritoneal Carcinoma
- Ovarian Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You have received a live vaccine, including live COVID-19 vaccines, within 28 days before starting the study treatment.You have a serious heart condition that is not well controlled.You have received any cancer treatment within the specified time periods mentioned in the study protocol.You have cancer that has spread to the brain or spinal cord and it has not been treated yet.You have already been treated with a medication that targets SIRPα, CD47, or CD40.If you have already received 2 or 3 cycles of platinum therapy, your cancer must have gotten worse within 6 months after your last dose of platinum.You have received a previous treatment with MIRV or another drug that targets FRα.You have serious problems with your stomach or intestines.
- Group 1: Mirvetuximab + SL-172154 (SIRPα-Fc-CD40L)
- Group 2: Pegylated Liposomal Doxorubicin + SL-172154 (SIRPα-Fc-CD40L)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the combination of Mirvetuximab and SL-172154 been authorized by the FDA?
"Our internal risk rating for Mirvetuximab + SL-172154 is 1 due to it being a Phase 1 trial, which implies limited data has been collected on its safety and efficacy."
What are the foremost objectives of this medical experiment?
"In this study, the primary outcome measured between first dose up to one year is assessing the safety and acceptability of SL-172154 when combined with PLD. Additionally, secondary objectives are observing the terminal elimination half-life (t1/2) of MIRV, calculating area under serum concentration time curve (AUC) for total antibody after single and multiple doses, as well as determining its associated terminal elimination half-life (t1/2)."
Is enrollment for this clinical trial still taking place?
"Clinicaltrials.gov denotes that this medical trial is currently enrolling participants, with its inception on August 18th 2022 and the latest update taking place on November 15th of the same year."
In which locales is this experiment involving human subjects taking place?
"The Sarah Cannon Research Institute, City of Hope in Duarte and START Midwest are the three primary clinical trial sites. Additionally, 4 other locations have been enlisted to assist with this project."
How many participants are eligible to take part in this clinical trial?
"Affirmative. According to the records of clinicaltrials.gov, this medical study has been open for recruitment since August 18th 2022 and was last amended on November 15th 2022. At the moment, 102 participants are required from 4 different sites."
Share this study with friends